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TITLE OF CASE Do not include “a case report” 
Obesity related hypogonadism: A reversible condition 
 
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
 
Obesity is associated with hypogonadism. Whilst this association is widely accepted, the 
underlying mechanisms remain unclear. Furthermore, obesity is a risk factor for 
hypogonadism and conversely hypogonadism may be a risk factor for obesity. We present 
the case of a 30-year-old morbidly obese man with hypogonadotrophic hypogonadism that 
underwent a Roux-en-Y gastric bypass operation. Following the surgical treatment of his 
obesity the testosterone level returned to normal with improvements in hypogonadal 
symptoms, which allowed discontinuation of exogenous testosterone therapy. This case 
report demonstrates reversal of hypogonadism following weight loss with restoration of 
gonadal function. 
 
BACKGROUND Why you think this case is important – why did you write it up? 
 
Obesity is highly prevalent with recent figures suggesting that 25-27% of the UK population 
aged 16 years or over are overweight or obese.[1,2] By 2050 obesity is predicted to be 
prevalent in as much as 60% of adult men, 50% of adult women and 25% of children 
(Foresight 2007).[3] It is well recognised that obesity is associated with an increased risk of 
heart disease, stroke, type 2 diabetes, obstructive sleep apnoea and certain cancers. 
However, less well described is the association between hypogonadism leading to sexual 
dysfunction and poor well being. Of interest, the prevalence of obesity in hypogonadal 
patients with sexual dysfunction is increasing.[4] 
 
The most recent National institute of Clinical Excellence (NICE) guidelines for Obesity 
management, published in August 2016, recommend that adults with a body mass index 
(BMI) above 50 kg/m2 are offered a referral for a bariatric surgical assessment. The rationale 
is to improve quality of life, reduce obesity-associated morbidity and to reduce the risk of 
premature mortality.[5] 
 
Bariatric surgery is by far the most effective way in improving the testosterone levels in 
obese hypogonadal patients as it results in higher weight reduction than other interventions 
such as low-fat diet and exercise. In fact bariatric surgery can have similar effect on 
testosterone levels with replacement therapy including testosterone gels and patches.[6]  
 
 
CASE PRESENTATION Presenting features, medical/social/family history 
 
A 30-year-old man was referred to the Endocrinology clinic with long-standing history of 
tiredness and a weight gain of 25 kg over a six-year period. He had a BMI of 47 kg/m2 with 
no obvious underlying endocrine cause. There was a maternal history of type 2 diabetes 
mellitus and hypothyroidism. He had co-existing depression and obstructive sleep apnoea 
and was not receiving any medication. He volunteered to have poor sexual function. 
Examination showed a weight of 139 kg, normal cardiovascular and respiratory system 
findings. He was clinically euthyroid, eupituitary with no signs of Cushing’s disease. The 
confrontation visual test was normal. Thyroid function tests on two separate occasions within 
the last three years had showed low free thyroxine (FT4) levels and normal thyroid-
stimulating hormone (TSH) levels.  
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There was evidence of hypogonadotrophic hypogonadism with a low testosterone level, 
inappropriately normal Luteneizing hormone (LH) and Follicle Stimulating hormone (FSH) 
levels. A short synachten test (SST) was performed which was normal. Because of the 
excess weight and the patient had claustrophobia an MRI scan of the pituitary gland could 
not be undertaken so a computed tomography (CT) scan of his pituitary gland was 
performed that was reported as being unremarkable. He was commenced on testosterone 50 
milligrams once daily by transdermal application. Despite this and being treated with 
continuous positive airway pressure (CPAP) the patient complained of tiredness and lethargy, 
and gained a further 12 kg over the next 12 months resulting in a weight of 151kg with a 
BMI of 51 kg/m2. He was started on replacement with levothyroxine at a dose of 50 
micrograms per day in view of his symptoms and weight gain and discharged from the 
endocrine clinic. A referral was made to the local Tier 3 bariatric clinic. 
 
When seen in Tier 3 weight assessment and management clinic he was commenced on 
treatment with orlistat and referred to dietetics services and to Tier 4 services for 
consideration of bariatric surgery. Sixteen months later he had sleeve gastrectomy resulting 
in excess weight loss of 58% one year after surgery but at 30 months his BMI was 41.7 
kg/m2 and weighed 124.8 kg with 36.5% excess weight loss due to poor diet. The patient 
was adamant that had an insufficient portion of his stomach removed and insisted to go on 
bypass. Last year, 45 months after his first operation, he had a Roux-en-Y gastric bypass 
that resulted in an extra 41 kg loss and now weighs 71 kg with a BMI of 24 kg/m2. His 
testosterone level significantly increased after the weight loss and currently is off the 
testosterone replacement therapy with improvement of his sexual function and quality of life. 

 
INVESTIGATIONS If relevant 
Full blood count, renal and liver and profiles were normal. 
His random cortisol level was 266 nmol/L, prolactin was 248 mU/L  
FSH was 3.9U/L, LH was 1.8 U/L, TSH at 4.2 mU/L with an FT4 of 11.9 pmol/L. 
His testosterone level prior replacement was 4.6nmol/L. 
His SST showed basal cortisol level of 370 nmol/L and 950 nmol/L at thirty minutes. 
CT scan of his pituitary gland, as there was an element of claustrophobia, was normal. 
 

 
 
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
 
The main differential diagnosis at the initial consultation with the Endocrinology team was a 
pituitary lesion causing secondary hypothyroidism or hyperprolactinemia. However CT 
pituitary scan did not reveal any pituitary tumour and prolactin levels were normal. There 
were no clinical or biochemical findings suggestive of Cushing’s syndrome. The patient was 
not on opiates and did not abuse alcohol. There was no history of anabolic steroids use or 
any severe/chronic illness. This established the diagnosis of obesity associated with 
hypogonadotrophic hypogonadism. 
 
TREATMENT If relevant  
 
For the impaired sexual function and the low testosterone levels, the patient was started on 
testosterone gel. This had no significant effect on his symptoms and was subsequently 
discontinued following the bariatric surgery. As he had abnormal thyroid function tests with 
symptoms possibly related to hypothyroidism associated with weight gain, he also had 
treatment with levothyroxine. 
After confirmation with sleep studies he was given continuous positive airway pressure 
treatment with some good effect. 
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He underwent two bariatric surgery procedures the first was a sleeve gastrectomy followed 
by a Roux-en-Y Gastric Bypass operation. The result was a 53% reduction of his body weight 
to 71 kg and a BMI of 24 kg/m2 with normalization of his testosterone levels to the highest 
ever level of 15.8 nmol/L, not on replacement therapy (table1). 
 
 
Table 1 - Biochemical characteristics of patient and changes after bariatric surgery 

 
    Before surgery  
 
      1 M after            
       surgery 
 
       8 M after     
        surgery  
 
Body mass index 
(kg/m2) 
 
          51 
 
         39           24 
Body Weight (kg) 
 
         152 
 
        112 
 
          71 
Total testosterone 
(nmol/L) 
 
         4.6 
 
        7.5          15.8 
LH (IU/L) 
 
         1.8 
 
        3.6           2.0 
 
FSH (IU/L) 
 
         3.9 
 
        3.9           6.3 
 
 
OUTCOME AND FOLLOW-UP  
This patient after the bariatric surgical procedure lost a significant amount of excess body 
weight and his quality of life improved. This lead to normalisation of the testosterone levels 
and improvement of his sexual life. It reduced as well the symptoms related to his OSA. 
To our knowledge he has not gained back any of the lost weight. 
He is now on supplements with vitamins and minerals after the operation.  
 
DISCUSSION Include a very brief review of similar published cases  
Obesity and male hypogonadism are often associated, as evidenced by many cross-sectional 
studies.[7]Data from prospective studies show that hypogonadal patients are at increased 
risk of becoming obese. Amongst obese patients the incidence of hypogonadism is 
high.[4,7]So there is a two-way relationship between the two conditions.[8] The results of a 
meta-analysis show that obesity treatment is very effective for the associated hypogonadism 
as well.[9]  
 
It is not entirely clear how obesity causes hypogonadism and several mechanisms have been 
proposed such as dietary-induced hypothalamic inflammation, along with a decreased 
gonadotropin-releasing hormone (GnRH) secretion.[10] The proportion of obese patients 
that seek medical treatment for sexual dysfunction is increasing. Good quality studies 
suggest that treatment with testosterone results in an increase in lean mass and a decrease 
in fat mass. So the combined effect on the body weight is negligible.[11] As previously 
mentioned the mechanism by which obesity causes hypogonadism is under debate and so far 
several theories are proposed such as the impairment of the hypothalamo-pituitary-gonadal 
axis and the disruption of the pulsatile manner of GnRH secretion.[12] Other proposed 
mechanisms include the increased levels of oestrogens, involvement of hormones like 
ghrelin, possible leptin resistance and increased levels of tumor necrosis factor alpha, that is 
known to cause apoptosis.[13] Finally impaired expression of several receptors like the 
glucose transporter-4 and the kisspeptin has been investigated.[14] 
 
In a meta analysis, examining the available data from clinical intervention studies, greater 
weight loss resulted in a greater rise in testosterone levels. Additionally, there was an 
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increase in sex hormone binding globulin (SHBG), calculated free testosterone, LH, FSH and 
reduction of oestradiol levels.[9] The intervention that had the best results in increasing 
testosterone levels was bariatric surgery by achieving more weight loss than others like life-
style changes. More specifically, the mean % body weight loss with bariatric surgery was 
32% as opposed to only 9% with diets that aimed to reduce calorie intake. The mean 
increase in testosterone levels was 9 nmol/L in the former and 3 nmol/L in the latter. 
The 
same increase in testosterone levels after bariatric surgery was observed with replacement 
therapy with gels/patches of testosterone.[8] So we can safely conclude that before 
proceeding to replacement therapy with testosterone, every effort should be made to loose 
weight, with bariatric surgery being by far the most successful.   
 
There is evidence that male hypogonadism may have a causal relationship to obesity. We 
know that androgens have an important role in male metabolism by influencing energy 
balance and lipolysis.[15] When the androgen receptor is activated this leads to a negative 
effect on visceral adiposity and a good example is androgen-deprivation therapies that often 
induce obesity.[16] Again, the molecular mechanism by which male gonadal dysfunction 
leads to obesity remain unclear. Evidence from studies show that is associated with 
impairments in hepatic gluconeogenesis, excessive fat accumulation in white adipose tissue 
and hyperlipidemia, independent of adipocyte lipid metabolism. So, impaired hepatic 
gluconeogenesis is proposed as a major pathway of obesity caused by male 
hypogonadism.[17] Further studies are needed to better analyze the molecular mechanisms 
underlying obesity caused by male gonadal dysfunction.  
 
As opposed to primary hypogonadism, obesity-associated hypogonadism is due to the 
increased conversion of androgen precursors to oestrogen in the large adipose tissue volume 
resulting in hyperestrogenemia. A recent study that looked into the response to testosterone 
therapy in hypogonadal men showed variation according to their BMI and more specifically 
demonstrate that severely obese hypogonadal men do not benefit from testosterone therapy 
as much as men with lower BMI.[18] So, testosterone treatment is not the answer in this 
case and every effort should be made to treat underlying obesity with the best way being 
bariatric surgery. The management of obesity is complex because it has an underlying 
genetic basis that can be exacerbated by lifestyle and eating habits.[19]  
 
It is evident that an integrated approach on obesity is necessary. Patients with severe 
obesity who have not responded to previous Tier interventions should have access to Tier 3 
services. A Tier 3 service is comprised of a multi-disciplinary team (MDT) of specialists, led 
by a clinician and typically including a physician, a specialist nurse, a specialist dietitian, a 
pshychologist and a physiotherapist. 
Engagement in Tier 3 services might lead to bariatric surgery which is a part of Tier 4 service 
and is supported by an MDT in the preoperative period and the postoperative period as well. 
 
 
 
 
 
 
 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
 
 There is a reactive association between obesity and male hypogonadism through 
complex pathogenetic mechanisms. 
 There is higher prevalence of symptomatic hypogonadism in obese patients.  
 An approach within a multidisciplinary team is the ideal one for having the best 
results in male obesity-related hypogonadism.  
 Bariatric surgery is by far the most effective way in improving the levels of 
testosterone in severely obese hypogonadal patients as it leads to the highest body 
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weight reduction. 
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